Genprex to evaluate effect of Oncoprex on checkpoint inhibition with MD Anderson

Genprex Inc. (NASDAQ:GNPX) will sponsor a preclinical program at the University of Texas MD Anderson Cancer Center (Houston, Texas) aimed at evaluating the effect of Genprex's Oncoprex on checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 therapies. MD Anderson will provide all necessary personnel, equipment, supplies, facilities and resources for Genprex to conduct the study.

Oncoprex, which comprises systemically delivered nanoparticles incorporating tumor suppressor candidate 2 (TUSC2; FUS1), is in Phase II testing to treat non-small cell lung cancer (NSCLC)...